124 related articles for article (PubMed ID: 3475378)
1. [Usefulness of measurement of serum CA125 levels in diagnosing and treating endometriosis].
Kobayashi H; Kanayama N; Hayata T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Jul; 39(7):1054-60. PubMed ID: 3475378
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of CA19-9 for endometriosis].
Watanabe J; Johboh T; Hata H; Kuramoto H
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):155-61. PubMed ID: 2313144
[TBL] [Abstract][Full Text] [Related]
3. [The mechanism of the increase in the serum CA125 concentration in patients with endometriosis].
Kobayashi H; Miyake W; Yamashita M; Kanayama N; Hayata T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Apr; 40(4):467-72. PubMed ID: 3163715
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma].
Iwasaka T; Ohkuma Y; Yoshimura T; Sugimori H
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):917-23. PubMed ID: 2426378
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CA125 as a circulating tumor marker for ovarian cancer.
Kuzuya K; Nozaki M; Chihara T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):949-57. PubMed ID: 3461071
[TBL] [Abstract][Full Text] [Related]
6. Serum CA 125 as a marker for patients with external endometriosis.
Takahashi K; Kijima S; Yoshino K; Shibukawa T; Kitao M
Int J Fertil; 1989; 34(2):143-8. PubMed ID: 2565317
[TBL] [Abstract][Full Text] [Related]
7. [The value of serum CA125 assays in the diagnosis of uterine adenomyosis].
Zhou Y; Wu B; Li H
Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):590-3. PubMed ID: 9275451
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
9. [Differential diagnosis between leiomyomata uteri and adenomyosis using CA 125 as a new tumor marker of ovarian carcinoma].
Takahashi K; Kijima S; Yoshino K; Shibukawa T; Moriyama M; Iwanari O; Sawada K; Matsunaga I; Murao F; Kitao M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Apr; 37(4):591-5. PubMed ID: 3857281
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
[TBL] [Abstract][Full Text] [Related]
11. [Fundamental and clinical study on source of CA 125 antigen in cul-de-sac fluid and translation into systemic circulation].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):390-6. PubMed ID: 2746065
[TBL] [Abstract][Full Text] [Related]
12. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
[TBL] [Abstract][Full Text] [Related]
13. [Value of CA125 (carbon hydrate tumor-associated antigen) and endometrial antibodies for the detections of endometriosis].
Yang F; Fang AH; Gu RF
Zhonghua Fu Chan Ke Za Zhi; 1994 Mar; 29(3):147-9, 189. PubMed ID: 8082430
[TBL] [Abstract][Full Text] [Related]
14. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
Chen DX; Li FQ
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
[TBL] [Abstract][Full Text] [Related]
15. [The clinical usefulness of the measurement of serum sialyl SSEA-1 antigen levels in patients with gynecologic diseases: as respects the comparative effectiveness of sialyl SSEA-1 and CA125].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):828-34. PubMed ID: 3166483
[TBL] [Abstract][Full Text] [Related]
16. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
[TBL] [Abstract][Full Text] [Related]
17. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
[TBL] [Abstract][Full Text] [Related]
18. [A fundamental and clinical investigation of cancer antigen 130 (CA 130) in the field of obstetrics and gynecology].
Inaba N; Okajima Y; Ota Y; Fukazawa I; Yamaguchi T; Sato N; Sudo H; Milanga M; Takamizawa H; Fujii S
Nihon Gan Chiryo Gakkai Shi; 1989 Oct; 24(10):2426-35. PubMed ID: 2614181
[TBL] [Abstract][Full Text] [Related]
19. Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary report.
Kafali H; Artuc H; Demir N
Eur J Obstet Gynecol Reprod Biol; 2004 Sep; 116(1):85-8. PubMed ID: 15294374
[TBL] [Abstract][Full Text] [Related]
20. Serum CA 125 levels in patients with endometriosis: changes in CA 125 levels during menstruation.
Masahashi T; Matsuzawa K; Ohsawa M; Narita O; Asai T; Ishihara M
Obstet Gynecol; 1988 Sep; 72(3 Pt 1):328-31. PubMed ID: 3165507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
